Skip to content
10-Q

Quarterly Report

Ibere Pharmaceuticals

0001410578-22-001616

← back to feed
Filed
May 16, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$323.63K
Short Term Debt Q1 2022 · Mar 31, 2022 $0
Cash And Equivalents Q1 2022 · Mar 31, 2022 $134.76K
Cash And Equivalents Q1 2022 · Dec 31, 2021 $458.39K
Stockholders Equity Q1 2022 · Mar 31, 2022 −$7.28M
Stockholders Equity Q1 2022 · Dec 31, 2021 −$10.85M
Current Liabilities Q1 2022 · Mar 31, 2022 $309.03K
Current Liabilities Q1 2022 · Dec 31, 2021 $372.44K
Total Liabilities Q1 2022 · Mar 31, 2022 $7.6M
Total Liabilities Q1 2022 · Dec 31, 2021 $11.54M
Current Assets Q1 2022 · Mar 31, 2022 $327.36K
Current Assets Q1 2022 · Dec 31, 2021 $693.39K
Total Assets Q1 2022 · Mar 31, 2022 $138.35M
Total Assets Q1 2022 · Dec 31, 2021 $138.71M
Net Income Q1 2022 · Mar 31, 2022 $3.57M
Operating Income Q1 2022 · Mar 31, 2022 −$302.61K